Description

Aralet (letrozole) Coated Tablets 2.5 mg. №30

Ingredients

Active ingredient: Letrozole 2.5 mg.
Inactive ingredients: lactose monohydrate, maize starch, colloidal silicon dioxide, sodium starch glycolate, magnesium stearate, hypromellose, macrogol 6000, titanium dioxide (E171).

Dosage

Recommended dosage: The usual dose is one tablet taken once daily, with or without food. Follow your healthcare provider’s instructions for the best results.

Indications

Aralet (letrozole) coated tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Contraindications

Do not use Aralet (letrozole) coated tablets if you are pregnant, breastfeeding, or allergic to letrozole or any of the inactive ingredients. Consult your doctor before starting this medication.

Directions

Take Aralet (letrozole) coated tablets exactly as prescribed by your healthcare provider. Do not exceed the recommended dosage or change the dosing schedule without consulting your doctor.

Scientific Evidence

Studies have shown that letrozole, the active ingredient in Aralet tablets, is effective in reducing the risk of cancer recurrence in postmenopausal women with hormone receptor-positive early breast cancer. Research published in the New England Journal of Medicine demonstrated the superior efficacy of letrozole over tamoxifen in this patient population.

Additional Information

It is important to attend regular follow-up appointments with your healthcare provider while taking Aralet tablets to monitor your response to treatment and assess for any potential side effects. Inform your doctor of any new symptoms or concerns that arise during treatment.

Pharmacological Effects: Letrozole is a nonsteroidal aromatase inhibitor that works by decreasing the amount of estrogen produced in the body. By lowering estrogen levels, letrozole helps slow or stop the growth of hormone receptor-positive breast cancer cells.

Clinical Trials: Clinical trials have demonstrated the efficacy of letrozole in improving disease-free survival and reducing the risk of cancer recurrence compared to tamoxifen in postmenopausal women with early breast cancer. These findings have established letrozole as a standard adjuvant treatment option in this patient population.